Jeffrey S. Glenn, M.D., Ph.D.

Publication Details

  • The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein VIROLOGY Lee, C., Ma, H., Hang, J. Q., Leveque, V., Sklan, E. H., Elazar, M., Klumpp, K., Glenn, J. S. 2011; 414 (1): 10-18


    The hepatitis C virus (HCV) non-structural (NS) 5A protein plays an essential role in the replication of the viral RNA by the membrane-associated replication complex (RC). Recently, a putative NS5A inhibitor, BMS-790052, exhibited the highest potency of any known anti-HCV compound in inhibiting HCV replication in vitro and showed a promising clinical effect in HCV-infected patients. The precise mechanism of action for this new class of potential anti-HCV therapeutics, however, is still unclear. In order to gain further insight into its mode of action, we sought to test the hypothesis that the antiviral effect of BMS-790052 might be mediated by interfering with the functional assembly of the HCV RC. We observed that BMS-790052 indeed altered the subcellular localization and biochemical fractionation of NS5A. Taken together, our data suggest that NS5A inhibitors such as BMS-790052 can suppress viral genome replication by altering the proper localization of NS5A into functional RCs.

    View details for DOI 10.1016/j.virol.2011.03.026

    View details for Web of Science ID 000290701100002

    View details for PubMedID 21513964

Stanford Medicine Resources:

Footer Links: